Revance Therapeutics (RVNC)

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
ESG framework mentions
In last year of SEC filings
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
AirCap and TradeCarbonCleanClimateClimate ChangeConservationEmissionEnergy EfficiencyEnvironmentEnvironmentalGreenhouse Gas EmissionIntensityLEEDLife CycleMaterialsNatureOffsetPackagePackagingPandemicPlanetPlasticRaw MaterialsRegenerativeRenewableToxicWasteWaterWater UsageAccessAfrican AmericanAsianBenefitsBlackCalifornia Consumer Privacy ActCitizenshipCommunityConsumer SentimentCultureCustomerCyberCyber SecurityCybersecurityD&IData PrivacyData SecurityDeathDemographicsDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee EngagementEmployee Resource GroupEngagementEthnicEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHispanicHuman CapitalHuman ResourcesIncidentInjuriesInjuryLatinxLGBTQMinorityOvertimePay EquityPay for PerformancePerquisitesPrivacyProduct QualityRacismRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainSupply Chain ManagementTalentTrainingUnionVolunteerWomenWorkforceWorkplace SafetyAction PlanAssessmentAssuranceAttorney GeneralAttorneys GeneralAuditBoard RefreshmentBonusBriberyChronicClassifiedClawbackCommitmentConflict of InterestCorporate GovernanceCorporate PurposeCorporate Social ResponsibilityDepartment ofESGEthicsExecutive CompensationExpertFinedFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentIndependent ChairInnovateInnovationInnovativeInvestigationKey Performance IndicatorLawsuitLeadershipLitigantLitigationLong-termMajorityMissionOther Public Company BoardsOverboardingOverseeOversightPerquisitePlaintiffPledgingProcurementPurposeR&DRecoupReputationReputationalReputational RiskResearch and DevelopmentResilientResponsibilityResponsibleSelf-evaluationSingle TriggerSpecial MeetingStockholder EngagementStockholder OutreachStrategySustainabilitySustainableTargetsTaxTax Gross UpTenureTransparencyTransparentVoting Rights
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
At the Company’s 2022 annual meeting of stockholders held on May 4, 2022, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2022 annual meeting (the “2022 Proxy Statement”), filed with the Securities and Exchange Commission on March 24, 2022. The results of the matters voted upon at the meeting were:
1.Each of the Class II nominees of the Company’s Board of Directors (the “Board”) were elected to hold office until the Company’s 2025 annual meeting of stockholders, as follows: Mark J. Foley: 36,119,897 shares of common stock voted for and 10,379,102 shares of common stock withheld; Christian W. Nolet: 34,035,661 shares of common stock voted for and 12,463,338 shares of common stock withheld, and Philip J. Vickers: 35,991,502 shares of common stock voted for and 10,507,497 shares of common stock withheld. There were a total of 8,744,469 broker non-votes for the election of the Class II nominees. The terms of office of the Class III directors, Jill Beraud and Carey O’Connor Kolaja, continue until the Company’s 2023 annual meeting of stockholders. The terms of office of the Class I directors, Angus C. Russell, Julian S. Gangolli and Olivia C. Ware continue until the Company’s 2024 annual meeting of stockholders.
2.The stockholders ratified the selection by the Audit Committee of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022, as follows: 55,040,277 shares of common stock voted for, 144,131 shares of common stock voted against, 59,060 shares of common stock abstaining and no broker non-votes.
3.The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2022 Proxy Statement, as follows: 36,151,026 shares of common stock voted for, 10,270,358 shares of common stock voted against, 77,615 shares of common stock abstaining and 8,744,469 broker non-votes.